人类猴痘的临床特征与管理:英国一项回顾性观察研究
该研究回顾2018至2021年英国7例猴痘患者的临床特征、病毒学动态及超说明书抗病毒治疗反应。发现上呼吸道猴痘病毒DNA排毒时间延长、1例深部组织脓肿PCR阳性,3例使用brincidofovir均出现肝酶升高而停药,1例使用tecovirimat无不良反应且排毒和病程较短。作者认为猴痘对具备HCID网络的资源充足医疗系统仍构成挑战,亟需抗病毒药前瞻性研究。
要点
- 7例猴痘患者中5例因PCR持续阳性隔离超过3周(范围22-39天)。
- 3例使用brincidofovir(200 mg每周一次口服)均出现肝酶升高导致停药。
- 1例使用tecovirimat(600 mg每日两次口服2周)无不良反应,排毒和病程较短(住院10天)。
核心结论
- 人类猴痘即使对拥有HCID网络的资源充足医疗系统也构成独特挑战。
- 皮肤病变消退后上呼吸道猴痘病毒DNA排毒时间延长,对现行感染防控指南提出挑战。
- 亟需针对该疾病开展抗病毒药物的前瞻性研究。
研究设计与样本
- 回顾性观察研究,通过回顾性病历复习纳入2018至2021年在英国诊断的7例猴痘患者。
- 纳入经国家HCID网络协调、在利物浦、伦敦和纽卡斯尔专用高后果传染病中心管理的所有患者。
- 回顾了2018年8月15日至2021年9月10日HCID(空气传播)网络成立以来的所有病例。
主要发现
- 7例患者中4例为男性、3例为女性;3例在英国获得感染,其中1名医护人员为院内感染,1例境外感染者在家庭聚集内传播给1名成人和1名儿童。
- notable disease features included viraemia, prolonged monkeypox virus DNA detection in upper respiratory tract swabs, reactive low mood, and one patient had a monkeypox virus PCR-positive deep tissue abscess.
- 5例因PCR持续阳性隔离超过3周(范围22-39天)。
- 3例接受brincidofovir(200 mg每周一次口服)治疗,均出现肝酶升高导致停药;1例接受tecovirimat(600 mg每日两次口服2周)治疗,无不良反应,与其余6例相比排毒和病程较短(住院10天)。
- 1例在出院6周后出现轻度复发。
关键数值与推荐
- brincidofovir用法为200 mg每周一次口服。
- tecovirimat用法为600 mg每日两次口服,疗程2周。
- 5例隔离时间超过3周,范围22-39天。
临床怎么用
- 作者认为皮肤病变消退后上呼吸道猴痘病毒DNA排毒时间延长对现行感染防控指南提出挑战。
- 作者认为亟需针对该疾病开展抗病毒药物的前瞻性研究。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cases of human monkeypox are rarely seen outside of west and central Africa. There are few data regarding viral kinetics or the duration of viral shedding and no licensed treatments. Two oral drugs, brincidofovir and tecovirimat, have been approved for treatment of smallpox and have demonstrated efficacy against monkeypox in animals. Our aim was to describe the longitudinal clinical course of monkeypox in a high-income setting, coupled with viral dynamics, and any adverse events related to novel antiviral therapies. METHODS: In this retrospective observational study, we report the clinical features, longitudinal virological findings, and response to off-label antivirals in seven patients with monkeypox who were diagnosed in the UK between 2018 and 2021, identified through retrospective case-note review. This study included all patients who were managed in dedicated high consequence infectious diseases (HCID) centres in Liverpool, London, and Newcastle, coordinated via a national HCID network. FINDINGS: We reviewed all cases since the inception of the HCID (airborne) network between Aug 15, 2018, and Sept 10, 2021, identifying seven patients. Of the seven patients, four were men and three were women. Three acquired monkeypox in the UK: one patient was a health-care worker who acquired the virus nosocomially, and one patient who acquired the virus abroad transmitted it to an adult and child within their household cluster. Notable disease features included viraemia, prolonged monkeypox virus DNA detection in upper respiratory tract swabs, reactive low mood, and one patient had a monkeypox virus PCR-positive deep tissue abscess. Five patients spent more than 3 weeks (range 22-39 days) in isolation due to prolonged PCR positivity. Three patients were treated with brincidofovir (200 mg once a week orally), all of whom developed elevated liver enzymes resulting in cessation of therapy. One patient was treated with tecovirimat (600 mg twice daily for 2 weeks orally), experienced no adverse effects, and had a shorter duration of viral shedding and illness (10 days hospitalisation) compared with the other six patients. One patient experienced a mild relapse 6 weeks after hospital discharge. INTERPRETATION: Human monkeypox poses unique challenges, even to well resourced health-care systems with HCID networks. Prolonged upper respiratory tract viral DNA shedding after skin lesion resolution challenged current infection prevention and control guidance. There is an urgent need for prospective studies of antivirals for this disease. FUNDING: None.
引用
- Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022. PMID: 35623380. doi:10.1016/S1473-3099(22)00228-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。